Hims & Hers Q3 rev $401.6M (+77% YoY), net income $75.6M, raises FY guidance

Hims & Hers Health, Inc.

2024-Q3 EPS reported $0.43 revenue$995,375,000

Q3 2024: Revenue $401.6M (+77% YoY), net income $75.6M (vs -$7.6M), Adj EBITDA $51.1M.
Subscribers 2.0M (+44% YoY); over 1M using personalized solutions; ex-GLP-1 sub growth 40% YoY.
FY 2024 guidance raised: Revenue $1.460-1.465B, Adj EBITDA $173-178M.
Weight loss offering: oral GLP-1 $100M annual run rate; 80K reports of supply shortage; planning liraglutide in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.